Entero Healthcare Solutions Ltd IPO

The Company operates in the large and highly fragmented Indian healthcare products distribution market and expect to benefit from market consolidation.

The Company is one of Indias largest and fastest growing healthcare products distribution platforms.

The Company has a track record of inorganic expansion and integration to grow its geographic reach, revenues and scale.

The Company has a differentiated business model offering comprehensive and integrated commercial and supply chain solutions.

The Company has a proprietary technology platform with integrated business intelligence tools and solutions.

The Company has a experienced, committed and qualified founding and professional management team with deep industry expertise and backed by healthcare focused investor.

Since its inception, the company has completed a number of acquisitions of distributors in India to expand its business and increase its customer base, and may continue to complete more acquisitions in the future. However, its may be unable to realize the anticipated benefits of past or future acquisitions successfully. Further, if the company is unable to identify expansion opportunities or experience delays or other problems in implementing our strategy of inorganic growth, its business, financial condition, results of operations, cash flows and prospects may be adversely affected.

The company has experienced negative cash flows from operating, investing and financing activities in the past and may continue to do so in the future.

The company may incur losses and its reputation may be adversely affected by the return of the company products by customers, arising from the distribution of expired, unsafe, defective, ineffective or counterfeit products, and product spoilage, breakage and damage during transportation or in storage. Its may also be subject to product liability claims.

Its lenders have imposed certain restrictive conditions on it under the company financing arrangements, which may adversely affect its ability to conduct its business and impair the company future growth plans.

Its operations are subject to high working capital requirements, and have incurred substantial indebtedness. Its inability to maintain an optimal level of working capital or financing required may impact its operations and profitability adversely.

The company has experienced losses in the Financial Years 2021, 2022 and 2023, and the six months ended September 30, 2022.

The company has pledged equity shares of certain of its Subsidiaries in favor of certain lenders and if events of default arise under the financing agreements, such lenders could invoke the relevant share pledge agreements, adversely affecting its business, results of operations, cash flows and prospects.

Its private label business may not be successful.

The Price Band, Offer Price, market capitalization to total revenue, total assets and EBITDA/EV based on the Offer Price of the Company, may not be indicative of the market price of the Company on listing or thereafter.

Its funding requirements and proposed deployment of the Net Proceeds are based on management estimates and have not been independently appraised by any bank or financial institution or any other independent agency, and may be subject to change based on various factors, some of which are beyond its control.